| Bioactivity | DB21, Galectin-1 Antagonist is a dibenzofuran conjugated peptidomimetic that acts as an allosteric inhibitor of galectin-1 (GAL1)binding to cell surface glycans. DB21, Galectin-1 Antagonis increases inhibition of angiogenesis and tumour growth in melanoma, lung adenocarcinoma and ovarian cancer models[1]. |
| Name | DB21, Galectin-1 Antagonist |
| CAS | 1623027-80-4 |
| Sequence | Ser-Val-Gln-{Nva}-Lys-Leu-{DBF}-Ile-Ile-Val-Lys-Leu-Asn-Ala |
| Shortening | SVQ-{Nva}-KL-{DBF}-IIVKLNA |
| Formula | C83H136N18O19 |
| Molar Mass | 1690.08 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Karina V Mariño, et al. Targeting galectin-driven regulatory circuits in cancer and fibrosis. Nat Rev Drug Discov. 2023 Apr;22(4):295-316. |
DB21, Galectin-1 Antagonist
CAS: 1623027-80-4 F: C83H136N18O19 W: 1690.08
DB21, Galectin-1 Antagonist is a dibenzofuran conjugated peptidomimetic that acts as an allosteric inhibitor of galectin
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.